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Annotations of gene structures and regulatory elements can inform genome-wide association studies (GWASs). However, choosing the
relevant annotations for interpreting an association study of a given trait remains challenging. I describe a statistical model that uses
association statistics computed across the genome to identify classes of genomic elements that are enrichedwith or depleted of loci influ-
encing a trait. The model naturally incorporates multiple types of annotations. I applied the model to GWASs of 18 human traits,
including red blood cell traits, platelet traits, glucose levels, lipid levels, height, body mass index, and Crohn disease. For each trait, I
used the model to evaluate the relevance of 450 different genomic annotations, including protein-coding genes, enhancers, and
DNase-I hypersensitive sites in over 100 tissues and cell lines. The fraction of phenotype-associated SNPs influencing protein sequence
ranged from around 2% (for platelet volume) up to around 20% (for low-density lipoprotein cholesterol), repressed chromatin was signif-
icantly depleted for SNPs associated with several traits, and cell-type-specific DNase-I hypersensitive sites were enriched with SNPs asso-
ciated with several traits (for example, the spleen in platelet volume). Finally, reweighting each GWAS by using information from func-
tional genomics increased the number of loci with high-confidence associations by around 5%.Introduction
A fundamental goal of human genetics is to create a catalog
of the genetic polymorphisms that cause phenotypic
variation in our species and to characterize the precise
molecular mechanisms by which these polymorphisms
exert their effects. An important tool in the modern
human genetics toolkit is the genome-wide association
study (GWAS), in which hundreds of thousands or mil-
lions of SNPs are genotyped in large cohorts of individuals
and each polymorphism is tested for a statistical associa-
tion with some trait of interest. In recent years, GWASs
have identified thousands of genomic regions that show
reproducible statistical associations with a wide array of
phenotypes and diseases.1
In general, the loci identified in GWASs of multifactorial
traits have small effect sizes and are located outside of
protein-coding exons.2 This latter fact has generated
considerable interest in annotating other types of genomic
elements apart from exons. For example, the ENCODE
project has generated detailed maps of histone modifica-
tions and transcription factor binding in six human cell
lines, partly to interpret GWAS signals that might act via
a mechanism of gene regulation.3 Methods for combining
potentially rich sources of functional genomic data with
GWASs could in principle lead to important biological
insights. The development of such a method is the aim
of this paper.
There are two lines of research that have motivated my
work on this problem. The first is what are often called
‘‘enrichment’’ analyses. In this type of analysis, the
researcher examines the most strongly associated SNPs in
a GWAS and tests whether they fall disproportionately in
specific types of genomic regions. These studies have1New York Genome Center, New York, NY 10013, USA; 2Department of Biolo
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The Amfound, for example, that SNPs identified in GWASs are en-
riched in protein-coding exons, in promoters, in UTRs,2,4
and among those that influence gene expression.5,6
Further, in some cases, SNPs associated with a trait are en-
riched in gene regulatory regions in specific cell types7–18
or near genes expressed in specific cell types.19,20 However,
the methods in these studies are generally not able to
consider more than a single annotation at a time (with a
few exceptions21,22). Further, they are not set up to answer
a question that I find important: consider two indepen-
dent SNPs with equivalent p values of 1 3 107 in a
GWAS for some trait (note that this p value does not reach
the standard threshold of 5 3 108 for ‘‘significance’’); the
first is a nonsynonymous SNP, and the second falls far from
any known gene. What is the probability that the first SNP
is truly associated with the trait, and how does this
compare to the probability for the second?
A potential answer to this question comes from the sec-
ond line of research that motivates this work. In associa-
tion studies where the phenotype being studied is gene
expression (studies of expression quantitative trait loci
[eQTLs]), statistical models have been developed to iden-
tify shared characteristics of SNPs that influence gene
expression.23–25 In a hierarchical modeling framework,
the probability that a given SNP influences gene expres-
sion can then depend on these characteristics. The key
fact that makes these models useful in the context of
eQTLmapping is that the genome contains a large number
of unambiguous eQTLs on which a model can be trained.
In the GWAS context, the number of loci unambiguously
associated with a given trait has historically been very
small; learning the shared properties of two or three loci
is not a job well suited to statistical modeling. However,
large meta-analyses of GWASs now regularly identify tensgical Sciences, Columbia University, New York, NY 10027, USA
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to hundreds of independent loci influencing a trait (e.g.,
Lango-Allen et al.26 and Teslovich et al.27). The merits
of hierarchical modeling in this context28–30 are thus
worth revisiting. Indeed, Carbonetto and Stephens31
have reported success in identifying loci involved in auto-
immune diseases by using a hierarchical model that incor-
porates information about groups of genes known to
interact in a pathway.
In this paper, I present a hierarchical model for jointly
analyzing GWASs and genomic annotations. I applied
this model to GWASs of 18 diseases and traits; for
each trait, I used the model to learn the relevant types
of genomic information from a set of 450 genome
annotations.Material and Methods
In this section, I detail the specifics of the hierarchical model;
details of the data used are in Appendix A. The proposed model
is most closely related to that developed by Veyrieras et al.23 in
the context of eQTL mapping. Conceptually, I split the genome
into independent blocks, such that the blocks are larger than
the extent of linkage disequilibrium (LD) in the population.
Each block is allowed to contain either a single polymorphism
that causally influences the trait or none. I model the prior prob-
ability that any given block contains an association and the con-
ditional prior probability that any given SNP in the block is the
causal one. The key is that these probabilities are allowed to
vary according to functional annotations—for example, gene-
rich regions might be more likely to contain associations, and if
there is an association, the causal polymorphism might be more
likely to fall in a transcription factor binding site. I then estimate
these priors by using an empirical Bayes approach. Software
implementing this model is available from GitHub (see Web
Resources).Computing the Bayes factor
The basic building block of the model is a linear regression model.
Consider a single SNP genotyped in N phenotyped individuals.
Assume that each individual has an associated measurement of a
quantitative trait (I describe a slight modification for case-control
studies later), and let y! be the vector of phenotypes. Let g! be the
vector of genotypes (coded 0, 1, or 2 according to counts of an
arbitrarily defined allele). I use a standard additive linear model:
E

yi
 ¼ aþ bgi: (Equation 1)
I would like to compare two models: one where b ¼ 0 and one
where b s 0. A natural way to compare these two models is the
Bayes factor,
BF ¼
Z
Pð y!j g!;H1ÞZ
Pð y!j g!;H0Þ
; (Equation 2)
where H1 and H0 represent the parameters of the alternative and
null models, respectively, and are integrated out.
To compute Equation 2, I use the approximate Bayes factor from
Wakefield.32 This Bayes factor has the practically important prop-560 The American Journal of Human Genetics 94, 559–573, April 3, 2erty that it can be calculated from a summary of the linear regres-
sion without access to the underlying genotype vector g!. For
completeness, I reiterate here the underlying model. If bb is the
maximum-likelihood estimator of b and
ﬃﬃﬃﬃ
V
p
is the SE of bb, Wake-
field32 suggests a model in which
bb  Nðb;VÞ: (Equation 3)
Wakefield32 places a normal prior on b, such that b ~ N(0, W).
Under this model, Equation 2 becomes
BF ¼
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
1 rp
exp

Z
2
2
r
; (Equation 4)
where r ¼ W/(V þ W) and Z ¼ bb= ﬃﬃﬃﬃVp (a standard Z-score). Thus,
from a Z-score, an estimate of V, and the prior variance W, one
can obtain a Bayes factor measuring how the statistical support
for a model in which a SNP is associated with a trait compares to
that for a model in which a SNP is not associated with a trait.
Note, however, that because of LD in the genome, any true causal
association will lead to multiple true statistical associations. In all
applications, I set W ¼ 0.1 as the prior, such that the majority of
the weight of the prior is on small effect sizes (results are robust
to some variation in this prior; Figure S16, available online).Hierarchical Model
Now consider a set of M SNPs, each of which has been genotyped
inN individuals in a GWAS. The goal is to build amodel to identify
the shared characteristics of SNPs that causally influence a trait.
Because of LD, there will be many genomic associations that are
not causal; however, these will all be restricted to a block around
the truly causal site. I thus split the genome into contiguous blocks
of size K SNPs (in all applications, I set K ¼ 5,000, although
doubling this block size had little effect on the results;
Figure S16), such that there are M/K blocks. The block size is
chosen to be much larger than the extent of LD in the population.
Let Pk be the prior probability that block k contains a causal SNP
associated with the trait. The probability of the data (the set of
observed phenotypes) is then
Pð y!Þ ¼
YM=K
k¼1 ð1PkÞP
0
k þPkP1k ; (Equation 5)
where P0k is the probability of the data in block k under the
model where there are no SNPs associated with the trait in
the block and P1k is the probability of the data in block k
under the model where there is one SNP associated with the trait
in the block. Further,
P1k ¼
X
i˛Sk
pikP
1
ik; (Equation 6)
where Sk is the set of SNPs in block k, pik is the prior probability
(conditional on there being an association in block k) that SNP i
is the causal SNP in the region, and P1ik is the probability of the
data under the model where this SNP is associated with the trait.
Note that this is not a multiple regression model that jointly
models the effects of multiple SNPs on a trait (as in, for example,
Carbonetto and Stephens31).
It is now possible to allow the prior probabilities—both Pk (the
prior probability on the block of SNPs containing an association)
and pik (the prior probability that SNP i is the causal SNP under014
the assumption that there is a single association in block k)—to
depend on external information. One would also like to avoid sub-
jective variation inPk and pik but instead learn from the data itself
which genomic annotations are most important. Specifically, I
model the regional prior probability as
ln

Pk
1Pk

¼ kþ
XL1
l¼1glIkl; (Equation 7)
where L1 is the number of region-level annotations in the
model, gl is the effect associated with annotation l, and Ikl takes
the value 1 if region k is annotated with annotation l and 0 other-
wise. For example, in practice I will estimate a g parameter for
regions of high or low gene density. I then model the SNP prior
probability as
pik ¼ e
xiX
j˛Sk
exj
; (Equation 8)
where
xi ¼
XL2
l¼1llIil; (Equation 9)
where L2 is the number of SNP-level annotations in themodel, ll is
the effect of SNP annotation l, and Iil takes the value 1 if SNP i falls
in annotation l and 0 otherwise. For example, in practice I will
estimate a l parameter for nonsynonymous SNPs.Fitting the Model
When the terms above are combined, the likelihood of the data
can be written down as
Lð y!j qÞ ¼
YM=K
k¼1 ð1PkÞP
0
k þPk
XK
i¼1pijP
1
ik
(Equation 10)
Lð y!j qÞ ¼
YM=K
k¼1 P
0
k
h
ð1PkÞ þPk
XK
i¼1pikBFi
i
;
(Equation 11)
where q contains all the parameters of themodel,most notably the
set of annotation parameters. I maximize this function by using
the Nelder-Mead algorithm implemented in the GNU Scientific
Library.Shrinkage Estimators of the Annotation Parameters
Althoughmaximizing Equation 10 gives themaximum-likelihood
estimates of all parameters, one concern is that there might be
some level of overfitting. When comparing models, I instead
shrink these parameters toward 0. Specifically, I define a penalized
log-likelihood function as
lð y!j qÞ ¼ lnðLð y!j qÞÞ  p
	XL1
l¼1g
2
l þ
XL2
l¼1l
2
l


:
(Equation 12)
The penalty p on the sum of the squared annotation parameters is
the one used in ridge regression.33 In ridge regression, parameter
estimates under this penalty are equivalent to the posterior means
of the parameter if the prior distribution of the parameter is
Gaussian;33 changing the tuning parameter p is equivalent to
changing the prior. I suspect that the interpretation in this model
is similar. Given that this penalized likelihood cannot be used forThe Amformal statistical tests, I tune the p parameter by cross-
validation. An alternative approach here would be to explicitly
put a prior on the enrichment parameters, but in the absence of
a conjugate prior, this would most likely add substantially to the
computational burden for little practical benefit.
Cross-validation
To compare models and tune the penalty p in the penalized
likelihood above, I used a 10-fold cross-validation approach. I
split the chromosomal segments into 10 folds. Let q
p
f be the
parameters of the model estimated without the data from fold f
and under penalty p, and let lf ðqpf Þ be the penalized log-likelihood
of the data in fold f under the model optimized without fold f.
Then,
l0ðqpÞ ¼ 1
10
X10
i¼1l

i
	
q
p
f


: (Equation 13)
Note that the size of the folds used in this cross-validationmeans
that each fold excludes more than an entire chromosome. This
means that no individual chromosome can have undue influence
on the parameters included in the model.
Model Choice
Consider a single phenotype and a set of L functional annotations
of SNPs (in applications, L is in the hundreds). Including all L SNP
annotations in the model is neither biologically interesting nor
computationally feasible. I thus set out to choose a relatively
sparse model that fits the data. I start with forward selection: for
each of the L annotations, I fit a model including a region-level
parameter for regions in the top third of the distribution of gene
density, a region-level parameter for regions in the bottom third
of the distribution of gene density, a SNP-level parameter for
SNPs from 0 to 5 kb from a transcription start site (TSS), a SNP-level
parameter for SNPs from 5 to 10 kb from a TSS, and a SNP-level
parameter for the annotation in question. I then identify the set
of annotations that significantly improve the model fit (as judged
by the likelihood from Equation 10). I then
1. Add the annotation that most significantly improves the
likelihood to the model.
2. Test a model (including the annotation and those that
have already been added) for each annotation identified as
having a significant marginal effect.
3. Go back to step 1 if any annotation remains significant.
At this point, there are generally a small number of annotations
in the model, but the model might be overfit. I then switch to
using the 10-fold cross-validation likelihood in Equation 13. I first
tune the penalty parameter p by finding the value of p that maxi-
mizes the cross-validation likelihood. I then
1. Drop each annotation from the model in turn and evaluate
the cross-validation likelihood. When dropping annota-
tions, I additionally try dropping the region-level annota-
tions on gene density and the SNP-level annotations on
distance to the nearest TSS.
2. Drop the annotation from the model and return to step 1 if
a simpler model has a higher cross-validation likelihood
than the full model.
3. Report themodel that has the highest cross-validation likeli-
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Approximating Vi
In order to compute the Bayes factor in Equation 4, one needs
an estimate of Vi, the variance of the estimated effect size of SNP
i. In principle, this is trivial output from standard regression
software; however, it is rarely reported. Instead, fi is the minor
allele frequency of SNP i and is computed from an external
sample of the same ancestry as the population in which the asso-
ciation study was done (I used data from the 1000 Genomes
Project34). Let Ni be the number of individuals in the association
study at SNP i (this can vary across SNPs because of missing
data). Then,
Viz
1
Nifi

1 fi
: (Equation 14)
Note that this variance is independent of the actual scale of the
measurements; this is appropriate because the Z-scores are inde-
pendent of the scale of the measurements as well.Case-Control Studies
For all of the above, I have considered studies of quantitative traits.
For a case-control study, assume that one has summary statistics
from logistic regression instead of linear regression. All aspects
of the model are identical, except for the approximation of Vi.
Define Ncase and Ncontrol as the numbers of case and control indi-
viduals, respectively. Now,32
Viz
Ncase þNcontrol
2NcaseNcontrolfi

1 fi
: (Equation 15)
The variance here is on a log-odds scale.Posterior Probabilities of Association
Once the model has been fit, it produces empirical estimates of
the prior probability that region k contains an association, bPk,
and of the prior probability that SNP i is the causal one, bpik (on
the condition that there is an association). Define a Bayes factor
summarizing the evidence of association in the region (see, for
example, Maller et al.35) as
BFRk ¼
X
i˛Sk
bpikBFi; (Equation 16)
where Sk is the set of SNPs in region k and BFi is the Bayes factor
for SNP i (Equation 4). The posterior probability that region k
contains an association (PPA for posterior probability of associa-
tion) is then
PPARk ¼
bPkBFRk=1 bPk
1þ bPkBFRk=1 bPk: (Equation 17)
One can also define the posterior probability that any given SNP
i in region k is the causal one under the model
PPAik ¼ bpikBFiP
j˛Sk
bpjkBFj: (Equation 18)
This is similar to the calculation in Maller et al.,35 except that the
prior probability pik is allowed to vary across SNPs.
Finally, one can define the posterior probability that any given
SNP is causal. This is the posterior probability that the region con-
tains a causal SNP multiplied by the posterior probability (condi-562 The American Journal of Human Genetics 94, 559–573, April 3, 2tional on there being an association in the region) that the SNP
is causal. If SNP i falls in region k, then
PPAi ¼ PPARkPPAik: (Equation 19)
Conditional Analysis
Because many of the annotations I consider are correlated, those
ultimately included in the combinedmodel for each trait (Figure 4)
might be representatives of a large group of correlated annota-
tions. For biological interpretation of the model, it is thus impor-
tant to know which of the other annotations are interchangeable
with those included in the model.
To test this, I took an approach of conditional analysis. Consider
two SNP-level annotations, with annotation parameters l1 and l2.
In a joint model, one would jointly estimate both l1 and l2. How-
ever, it is interesting to know whether the second annotation adds
information above and beyond that provided by the first annota-
tion. I thus first estimate l1 and then fix this parameter to its
maximum-likelihood value, bl1. I then estimate ðl2bl1Þ—that is, I
obtain the maximum-likelihood estimate and 95% confidence
interval (CI) of l2 conditional on a fixed value of l1. If this CI
does not overlap 0, then this is evidence that the second annota-
tion adds more information to the model than does the first
annotation.
In practice, I first fit the combined model as described in the
section ‘‘Model Choice’’ above. I then returned to the set of
annotations that had significant marginal associations. For each
annotation in the combinedmodel, I took each of the other anno-
tations in turn and tested whether the included annotation was
significantly more informative than the nonincluded annotation.
Figure 4 and Figure S12 display the total number of annotations
represented by each one included in the combined model.
Imputation of Summary Statistics
I used ImpG v.1.036 under the default settings to impute summary
statistics from all GWASs. I used as a reference panel all haplo-
types from European individuals in phase 1 of the 1000 Genomes
Project and only used SNPs with a minor allele frequency greater
than 2%. The reference haplotype files were derived from the
1000 Genomes integrated phase 1 v.3.20101123 calls (Web Re-
sources). I used all 379 individuals labeled ‘‘European.’’ After
imputation, I removed all imputed SNPs with a predicted accu-
racy (in terms of correlation with the true summary statistics)
less than 0.8. Overall, for each GWAS, about 75%–80% of SNPs
with a minor allele frequency over 10% were successfully imputed
(Figure S1).
To verify that imputation did not induce inflation of the test
statistics, I computed the genomic-control inflation factor, lGC,
37
before and after imputation (Table S1). In all studies, inflation
decreased after imputation, sometimes leading to a marked defla-
tion in the test statistics. This is consistent with previous observa-
tions from using this software36 and is caused by the imputation’s
shrinkage prior, which is imposed for strict avoidance of false-
positive associations.
Simulations
To test the performance of the model, I performed simulations
that used data from a GWAS of height.26 Using the imputed sum-
mary statistics, I split the genome into blocks of 5,000 SNPs and
then extracted the blocks with a genome-wide significant SNP014
reported in Lango Allen et al.26 In each block, I had a reported
Z-score for each SNP. To simulate annotations, I called the SNP
with the smallest p value in the region the ‘‘causal’’ SNP. I then
simulated annotations by placing all noncasual SNPs in an anno-
tation with rate r1 and all casual SNPs in the annotation with rate
r2. I also varied the numbers of blocks included in the model. In
each simulation, I randomly assigned SNPs to annotations accord-
ing to determined rates and then ran themodel under the assump-
tion that Pk ¼ 1, that is, all blocks contain a causal SNP. I then
calculated power as the fraction of simulations in which the CIs
of the annotation effect did not overlap 0.
I chose parameter settings of r1 and r2 such that the enrichment
factors were similar to those in observed data (log2 enrichment of
1.4 and 2.6). I chose r1 to be either 0.2 or 0.1. For each set of param-
eters, I simulated 100 annotations and ran themodel separately on
each. Shown in Figure S2 is the power of the model. As expected,
power increased as r1 or the effect size increased and as the number
of loci increased.
Robustness to Choice of Prior and Window Size
The model contains two parameters that are set by the user—the
prior variance W on the effect size and the window size defining
‘‘independent’’ blocks of the genome. I empirically tested the
robustness of the model to variation in these parameters by using
the Crohn disease data set. I ran the model on each annotation
by using W ¼ 0.1 and W ¼ 0.5 and additionally including (as in
the main analyses) region-level parameters for regions in the top
third and bottom third of the distribution of gene density and
SNP-level parameters for SNPs located from 0 to 5 kb from a TSS
and SNPs 5–10 kb from a TSS. Plotted in Figure S16A are these
annotation parameter estimates for all annotations where the
95% CIs did not overlap 0 in at least one run. The estimates
from the two runs with different priors are highly correlated. I
additionally tested window sizes of 5,000 SNPs and 10,000 SNPs
(both with W ¼ 0.1). The annotation effect estimates from these
two window sizes are plotted in Figure S16B and again are highly
correlated.
Quantifying the Relative Roles of Coding versus
Noncoding Changes in Each Phenotype
To generate Figure 3, I fit a model to each GWAS; this model
included region-level annotations for regions in the top third
and bottom third of the distribution of gene density and SNP-level
annotations for nonsynonymous SNPs and SNPs within 5 kb of a
TSS. Shown in Figure 3A are the estimates of the enrichment
parameter for nonsynonymous SNPs. At each SNP, the result of
this model is the posterior probability that the SNP is casual (see
Equation 19). If this posterior probability at SNP i is PPAi, then
the fraction of causal SNPs that are nonsynonymous, fNS, is
fNS ¼
P
iPPAiI
NS
iP
iPPAi
; (Equation 20)
where INSi is an indicator variable that takes value 1 if SNP i is
nonsynonymous and 0 otherwise. To get error bars on this frac-
tion, I performed a block jackknife. I split the genome into 20
blocks with equal numbers of SNPs. If f
j
NS is the estimate of the
fraction of casual SNPs that are nonsynonymous (excluding
block j), then
SE ¼
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
19
20
X20
j¼1
	
f jNS  f NS

2r
; (Equation 21)The Amwhere f NS ¼ ð1=20Þ
P20
i¼1f
i
NS. Figure S3 shows the corresponding
results for synonymous SNPs.Interaction Effects in Annotation Models
As noted in the Results, there were two cases in which the sign
of the annotation effect flipped between the single annotation
models and the combined models. These were Crohn disease (Ta-
ble S6) and red blood cell count (Table S18). For red blood cell
count, note that SNPs influencing this trait are enriched in the
annotation of DNase-I hypersensitive sites in the fetal renal pelvis
when this annotation is considered alone (log2 enrichment of
2.48, 95% CI [0.04, 4.17]). This annotation is correlated with the
fetal stomach annotation, which has a log2 enrichment of 4.83
(95% CI [3.30, 6.45]) when treated alone. The SNPs in both of
these annotations have a log2 enrichment of 2.41 (95% CI
[1.83, 4.23]), which leads to the interaction effect. Essentially,
the signal in the fetal stomach is driven by those SNPs that fall
in DNase-I hypersensitive sites in the fetal stomach, but not the
fetal renal pelvis. This suggests that there are a subset of DNase-I
hypersensitive sites that are of particular interest for this pheno-
type. The interpretation of the Crohn disease example is similar.Calibrating a ‘‘Significance’’ Threshold
For each genomic region, themethod estimates the posterior prob-
ability that the region contains a SNP associated with a trait. If the
model were a perfect description of reality, this probability could
be interpreted literally. However, because the model is not perfect,
I sought a more empirical calibration. I used the fact that I initially
ran themethod on theGWAS data reported by Teslovich et al.27 on
four lipid traits. Since then, a GWAS with more individuals
(although at a considerably smaller number of SNPs) has been
reported for these four traits.17 This latter study contained many
of the individuals from the former (which had approximately
90,000 individuals), as well as about 80,000 more individuals.
However, the additional individuals were genotyped in theMetab-
ochip,38 which has fewer than 200,000 markers, rather than the
more dense standard GWAS arrays. This means that some regions
of the genome do not benefit from the larger sample size.
For each region of the genome for each of the four traits, I built
a table containing the minimum p value from Teslovich et al.,27
the PPA in the region (computed with the data from Teslovich
et al.27), the minimum p value from the 2013 paper,17 and the
sample size used for calculating this minimum p value (from the
2013 paper17). I discarded regions where sample size at the SNP
with the minimum p value in the replication data set was smaller
than 120,000 (given that in these regions, there are essentially no
new data). I then coded each region as a ‘‘true positive’’ if the min-
imum p value from the 2013 paper17 was less than 53 108 and a
‘‘true negative’’ otherwise. In Figure S15, I plot the number of true
positives and false positives that exceeded various p value and PPA
thresholds. Note that because the data in the 2013 paper17 are not
independent of those in Teslovich et al.,27 this comparison is not
appropriate for evaluating the relative performance of p values
versus the PPA. The goal was simply to find a PPA threshold
with similar performance in terms of reducing the number of false
positives as the standard p value threshold of 5 3 108.
By visual inspection, I set a PPA threshold at 0.9 (Figure S15). At
this threshold, the model identified 45 true positives and 0 false
positives for high-density lipoprotein (HDL), 43 and 1 for low-
density lipoprotein (LDL), 47 and 0 for total cholesterol (TC),
and 27 and 0 for triglycerides (TGs). These are similar to theerican Journal of Human Genetics 94, 559–573, April 3, 2014 563
numbers for a p value threshold of 5 3 108 (Table S21).
Combining the loci identified by both methods led to 48 loci for
HDL (versus 43 with a p value threshold), 44 for LDL (versus
40), 51 for TC (versus 51), and 30 for TGs (versus 29). This is on
average an increase of 6% in the number of loci identified. Note
that this percentage is most likely a lower bound, given that the
p values in the replication study are naturally highly correlated
to those in the initial study because they use many of the same in-
dividuals. A proper comparison would use a completely separate,
large set of individuals to determine true positives and true nega-
tives, but such samples are not yet available.Identification of Subthreshold, High-Confidence
Associations
For each fitted model (using the parameters from Tables S3–S20
estimated with the penalized likelihood), I calculated the PPA in
each genomic region. I then identified all regions that had a PPA
greater than 0.9 but a minimum p value less than 5 3 108. For
each remaining region, I identified the ‘‘lead’’ SNP as the SNP
with the largest posterior probability of being the causal SNP in
the region. If this SNP was within 500 kb of a SNP with p < 5 3
108 (this can happen because I use nonoverlapping windows,
and sometimes the best SNP is at the edge of the region), I removed
it. I also manually removed two regions (surrounding rs8076131
in Crohn disease and surrounding rs11535944 in HDL) where
the ‘‘new’’ association was in LD with a previously reported SNP
over 500 kb away. Table S22 shows the remaining SNPs; these
regions are high-confidence associations that did not reach tradi-
tional genome-wide significance.Results
I assembled a set of 18 GWASs with publicly available sum-
mary statistics and a large number of loci (at least around
20) associated with the trait of interest. These included
studies of red blood cell traits,15 platelet traits,39 Crohn
disease,40 body mass index (BMI),41 lipid levels,27
height,26 bone mineral density,42 and fasting glucose
levels.43 I used ImpG36 to impute the summary statistics
from each study for all common SNPs identified in Euro-
pean populations by the 1000 Genomes Project.34 Overall,
association statistics for around 80% of common SNPs
were successfully imputed (Figure S1). I then assembled a
set of genome annotations while paying specific attention
to annotations available for many cell types because
important regulatory elements might be active only in
specific cell types. The main sources of genome annota-
tions were 402 maps of DNase-I hypersensitivity in a
wide range of primary cell types and cell lines.11,44 I also
included as annotations the output from ‘‘genome seg-
mentation’’ of the six main ENCODE cell lines;45 for
each section of the genome in each cell line, Hoffman
et al.45 report whether the histone modifications in the
region are consistent with enhancer activity, TSSs, pro-
moter-flanking regions, CTCF binding sites, or repressed
chromatin. Finally, I included elements of gene structures
(protein-coding exons and 30 and 50 UTRs). In total, I
used data from 18 traits and 450 genomic annotations.564 The American Journal of Human Genetics 94, 559–573, April 3, 2For each trait, I set out to identify which of the 450
annotations (if any) were enriched with genetic variants
influencing the trait. To do this, I developed a hierarchical
model that learns the shared properties of loci influencing
a trait. The full details of the model are presented in the
Material and Methods but can be summarized briefly.
Conceptually, I break the genome into large, nonoverlap-
ping blocks (with an average size of 2.5 Mb). Let the prior
probability that any block k contains an association bePk.
If there is an association in block k, then let the prior prob-
ability that any SNP i is the causal SNP be pik. The model
allows both Pk and pik to depend on annotations of the
region and SNP, respectively, and estimates these quanti-
ties on the basis of the patterns of enrichment across the
whole genome. I tested this approach by using simulations
based on real data from a GWAS of height (Material and
Methods).
The methodology is best illustrated with an example. I
started with an analysis of a GWAS of HDL levels.27 I first
took each genomic annotation individually and estimated
its level of enrichment with (or depletion of) loci that influ-
ence HDL (in the model, I additionally included a regional
effect of gene density and a SNP-level effect of distance to
the nearest TSS; see the Material and Methods for details).
Figure 1A shows the top 40 annotations, ordered by how
well each improved the fit of the model. Loci that influ-
ence HDL were most strongly enriched in enhancers iden-
tified in the HepG2 cell line and most strongly depleted
from genomic regions repressed in that same cell line.
HepG2 cells are derived from a liver cancer; the relevance
of this cell line to a lipid phenotype makes intuitive sense.
However, there were many other additional (correlated)
genome annotations enriched with loci that influence
HDL (Figure 1A). I thus built a model including multiple
annotations; to mitigate overfitting in this situation, I
used a cross-validation approach (Material and Methods).
The best-fitting model is shown in Figure 1B. It includes
both enhancers and repressed chromatin identified in
HepG2 cells, as well as coding exons and chromatin
repressed in K562 cells. Because many of the annotations
are correlated, those included in the combined model are
the ‘‘best’’ representatives of sets of related annotations. I
thus used conditional analysis to define the set of annota-
tions represented by each member of the combined model
(Material and Methods; Figure 1A).
A convenient side effect of fitting an explicit statistical
model relating properties of SNPs to the probability of
association is that the functional information can be
used for reweighting the GWAS (Material and Methods). I
used the combined model for HDL to reweight the asso-
ciation statistics across the genome (Figure 1C). There
were several genomic regions with strong evidence of asso-
ciation with HDL (PPA over 0.9) only when the model
incorporating functional information was used. Figure 2
shows one such region near the gene NR0B2 (MIM
604630). The model identified the SNP rs6659176 as the
most likely candidate to be the causal polymorphism in014
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Figure 1. Application of the Model to
HDL Cholesterol
(A) Single-annotation models. I fit the
model to each annotation individually,
including a SNP-level effect for SNPs 0–5
kb from a TSS, a SNP-level effect for SNPs
5–10 kb from a TSS, a region-level effect
for regions in the top third of gene density,
and a region-level effect for regions in the
bottom third of gene density. Plotted are
the maximum-likelihood estimates and
95% CIs of the enrichment parameter for
each annotation. Annotations are ordered
according to how much they improved
the likelihood of the model (at the top
are those that improved the likelihood
the most). In red are the annotations
included in the joint model, and in pink
are the annotations that are statistically
equivalent to those included in the com-
bined model.
(B) Joint model. Using the algorithm
described in the Material and Methods, I
built a model combining multiple annota-
tions. Shown are the maximum-likelihood
estimates and 95% CIs of the enrichment
effects of each annotation. Note that
although these are the maximum-likeli-
hood estimates, model choice was per-
formed with a penalized likelihood. In
parentheses next to each annotation
(except for those relating to distance to
TSSs) is the total number of annotations
statistically equivalent to the included
annotation in a conditional analysis.
(C) Reweighted GWASs. I reweighted the GWASs by using the model with all the annotations in (B) (under the penalized enrichment
parameters from Table S9). Each point represents a region of the genome, and shown are the posterior probabilities of association
(PPAs) of the regions in the models with and without the annotations.this region. This SNP has a p value of 1.53 106. However,
this SNP falls in a coding exon (in fact, it is nonsynony-
mous), leading the model to conclude that this p value is
in fact strong evidence of association. Indeed, larger
studies of HDL have confirmed the evidence of association
in this region (p value of 9.73 1016 at rs12748152, which
has r2 ¼ 0.85 with rs665917617). This region, although not
this particular SNP, was also identified in a scan for SNPs
influencing multiple lipid phenotypes.46
I applied this method to all 18 traits. I was first interested
in estimating for each trait the fraction of associations that
can be explained by nonsynonymous polymorphisms
versus polymorphisms that do not influence protein
sequences. For each trait, I fit a model including promoters
(SNPs within 5 kb of a TSS) and nonsynonymous polymor-
phisms. For all traits, nonsynonymous polymorphisms
were enriched among those that influence the trait,
although this enrichment was not statistically significant
for all traits (Figure 3A). In contrast, synonymous polymor-
phisms were generally not enriched among polymor-
phisms that influence traits, with a few notable exceptions
(such as height and Crohn disease, see Figure S3). I then
used these enrichments to estimate for each trait the frac-
tion of associations that are driven by nonsynonymous
polymorphisms (Material and Methods). This fraction var-The Amied from around 2% to around 20% and had an average of
10% (Figure 3B). I conclude that the relative importance of
changes in protein sequence versus gene expression most
likely varies across traits.
I then used all 450 genome annotations to build models
of enrichment for each trait. As for HDL, I first estimated
enrichment levels individually for each annotation (Fig-
ures S4–S12). Clustering phenotypes according to these
enrichment levels recapitulated many known relation-
ships between traits (Figure S13). I then generated a
combined model for each trait. The parameters of the
combined models are shown in Figure 4 and Figure S14,
and details of the exact annotations are in Tables S2–S20.
In general, the models generated with this method were
sparse and biologically interpretable. A few general pat-
terns emerged from this analysis. Apart from the repeated
occurrence of annotations related to protein-coding genes,
marks of repressed chromatin were often significantly
depleted for SNPs influencing traits. For example, SNPs
influencing Crohn disease were depleted from repressed
chromatin identified in a lymphoblastoid cell line
(Figure 4D; log2 enrichment of 1.83, 95% CI [3.06,
0.78]), SNPs influencing height were significantly
depleted from repressed chromatin in HeLa cells
(Figure 4I; log2 enrichment of 1.5, 95% CI [2.39,erican Journal of Human Genetics 94, 559–573, April 3, 2014 565
Figure 2. Regional Plot Surrounding
NR0B2
The top panel shows a plot of the p values
for association with HDL levels at each
SNP in this region. In the middle panel is
the fitted empirical prior probability (con-
ditional on there being a single causal SNP
in the region) that each SNP is the causal
one in the region. This prior was estimated
with the combined model with the anno-
tations in Figure 1B. In the lower panel
are the positions of the annotations
included in the model. The reported p
value indicated by an asterisk is for
rs12748152, which has r2 ¼ 0.85 with
rs6659176.0.71]), and SNPs influencing red blood cell volume were
significantly depleted from repressed chromatin in an
erythroblast-derived cell line (Figure 4F; log2 enrichment
of 3.91, 95% CI [6.25, 2.38]).
I additionally observed cell-type-specific enrichments in
enhancer elements and DNase-I hypersensitive sites for
SNPs that influence traits. Most of the observed enrich-
ments can be readily interpreted in light of the known
biology of the trait. For example, SNPs that influence
platelet volume and platelet count were enriched in open
chromatin identified in CD34þ cells, known to be on the
cell lineage that leads to platelets47 (Figures 4A and 4B;
log2 enrichment of 1.81, 95% CI [0.59, 2.86] for platelet
count; log2 enrichment of 3.02, 95% CI [1.69, 4.26] for
platelet volume), and SNPs that influence corpuscular
hemoglobin concentration were enriched in open chro-
matin identified in K562 cells, a cell line derived from a
cancer of erythroblasts (Figure S14E; log2 enrichment of
2.67, 95% CI [0.61, 4.44]). For some traits, however, the
connection between the trait and the tissues identified is
not immediately obvious. For example, SNPs associated
with platelet density were enriched in open chromatin in
the spleen (Figure 4A; log2 enrichment of 1.93, 95% CI
[0.59, 3.14]), and SNPs associated with height were en-
riched in open chromatin inmuscle (Figure 4I; log2 enrich-
ment of 2.27, 95%CI [1.51, 3.02]; note that although there
were a large number of annotations equivalent to this566 The American Journal of Human Genetics 94, 559–573, April 3, 2014annotation of open chromatin in
fetal muscle, all of them were muscle
related; see Figure S5B).
For two traits—Crohn disease
(Figure 4D) and red blood cell count
(Figure S14G)—I noticed that annota-
tions initially identified as enriched
with SNPs influencing the trait ended
up in the combined model as being
depleted of SNPs influencing the trait.
On further examination (Material
and Methods), I found that these
effects were due to statistical interac-
tions. For example, when treatedalone, SNPs that influence Crohn disease were enriched
in DNase-I hypersensitive sites identified in fetal fibro-
blasts from the abdomen (log2 enrichment of 3.17, 95%
CI [1.66, 4.36]). However, DNase-I hypersensitive sites
identified in fetal fibroblasts from the back showed an
even stronger enrichment (log2 enrichment of 4.21, 95%
CI [2.99, 5.29]), and sites in common between the two
annotations were intermediate (log2 enrichment of 3.74,
95% CI [2.29, 4.89]). This led to an interaction where in
the joint model, the contribution of the DNase-I hyper-
sensitive sites identified in fetal abdominal fibroblasts
was negative. Although this is a statistical explanation
for this observation, the biological explanation is not
immediately clear. It seems likely that DNase-I hypersensi-
tive sites are a heterogeneous set of different classes of
elements and that different experiments are more sensi-
tive, for either technical or biological reasons, to subsets
of these elements.
Finally, I explored the potential of this model to identify
additional high-confidence associations (as in Figure 2). In
order to do this, one needs a threshold for ‘‘significance’’ in
this model, ideally with similar properties as the standard p
value threshold of 5 3 108. To calibrate the method, I
used the fact that I initially applied the method to a
lipid-trait study that identified about 100 loci in a sample
size of around 90,000 individuals.27 Since then, larger
studies have raised the number of loci associated with lipid
AB
Figure 3. Estimated Role of Protein-Coding Changes in Each
Trait
(A) Estimated enrichment of nonsynonymous SNPs. For each trait,
I fit a model including an effect of nonsynonymous SNPs and an
effect of SNPs within 5 kb of a TSS. Shown are the estimated
enrichment parameters and 95% CIs for the nonsynonymous
SNPs.
(B) Estimated proportion of GWAS hits driven by nonsynonymous
SNPs. For each trait, using the model fit in (A), I estimated the
proportion of GWAS signals driven by nonsynonymous SNPs.
This estimate and its SE are shown.traits to 157.17 If a locus with a p value of 5 3 108 in the
larger study is considered a true positive and a locus that
does not reach this threshold in the larger study is consid-The Amered a true negative, it is possible to calibrate a threshold
for a PPA by using the replication data (Supplemental
Data). I found that a threshold of a regional PPA of 0.9
performed similarly to a stringent p value threshold
(Figure S15). Combining the loci from both the standard
p value approach and the approach presented here resulted
in an approximately 5% increase in the number of identi-
fied loci while still maintaining a false-positive rate close to
0 (Figure S15 and Table S21). This is only a modest gain in
power; that said, by applying this method to all 18 traits, I
identified 49 loci that did not reach a standard statistical-
significance threshold of 5 3 108 but had a PPA over 0.9
(Table S22). On the basis of the above results for lipids,
the level of evidence that these loci are true positives is
approximately the same as that for loci that have p ¼
53 108 in a standard GWAS. Indeed, themajority of these
loci have since been identified in larger cohorts than those
used in this paper (Table S22).Discussion
In this paper, I have developed a statistical model for iden-
tifying genomic annotations that are most relevant to the
biology of a given phenotype. I have shown that this
model is able to scan through hundreds of genomic anno-
tations to identify a sparse set of biologically interpretable
annotations without prior knowledge of the biology of the
phenotype.Linking GWASs to Biology
Perhaps the most striking observation is that chromatin
annotated as repressed in a given cell type was often
depleted of SNPs that influence traits. Given that approxi-
mately 60%–70% of the genome falls in this annotation in
any given cell type (Supplemental Data), this information
could dramatically limit the number of SNPs considered
during finemapping of loci identified in GWASs. Addition-
ally, I identified several nonobvious connections between
tissue and phenotypes. For example, SNPs that influence
platelet volume were enriched in DNase-I hypersensitive
sites in the spleen (Figure 4A). Although the spleen func-
tions in the removal of platelets from the bloodstream,
the connection between its function and platelet volume
is unclear. An important next step will be to connect the
identified noncoding variants in regulatory regions to
changes in gene expression; this is presumably the mecha-
nism by which they exert an effect on phenotypes.
Methods for inferring the casual chain connecting varia-
tion in DNase-I sensitivity, variation in gene expression,
and variation in phenotypes46,48–51 will be essential.Modeling Assumptions
I have made several modeling assumptions that merit
discussion. First, by splitting the genome into blocks on
the basis of numbers of SNPs, I have made the implicit
assumption that the probability that a genomic regionerican Journal of Human Genetics 94, 559–573, April 3, 2014 567
Figure 4. Combined Models for Nine Traits
For each trait, I built a combined model of annotations by using the algorithm presented in the Material and Methods. Shown are the
maximum-likelihood estimates and 95% CIs for all annotations included in each model. Note that although these are the maximum-
likelihood estimates,model choice was donewith a penalized likelihood (Material andMethods). For the other nine traits, see Figure S14.
In parentheses next to each annotation (except for those relating to distance to TSSs) is the total number of annotations that are statis-
tically equivalent to the included annotation in a conditional analysis (Material and Methods). The annotation of DNase-I hypersensi-
tive sites in fetal fibroblasts from the abdomen (marked by an asterisk) had a positive effect when treated alone; see the main text for
discussion.contains a SNP associated with a given phenotype depends
on the SNP density rather than the physical size—that is, a
short genomic region with a large number of SNPs is a
priori as likely to have an association as a long genomic
region with few SNPs. I have also made a more restrictive
assumption that there can be only a single causal SNP in568 The American Journal of Human Genetics 94, 559–573, April 3, 2a given genomic region. This assumption is a natural start-
ing point, but as GWAS sample sizes increase even more, it
will begin to be untenable. Advances in methods for joint
analysis of multiple SNPs (e.g., Yang et al.52) might provide
a way forward in this situation. Finally, note that themodel
is limited by the types of genomic annotations that are014
available, and the best annotations identified in the model
might be ‘‘proxies’’ for the truly relevant annotations. For
example, SNPs associated with height were enriched in
DNase-I hypersensitive sites identified in the fetal lung
(Figure 4I); taken literally, this would suggest that some
SNPs influence height through lung development. An
alternative possibility, however, is that patterns of open
chromatin in the lung (which is of course a heterogeneous
tissue) are useful proxies for patterns of open chromatin in
a cell type that has not been profiled; this hypothetical cell
type could in principle be present in any tissue.
Prospects for Fine Mapping GWAS Loci with
Functional Genomic Data
I have primarily focused on using the model to identify
annotations relevant to a trait of interest, although I
have also explored using this information to identify
high-confidence associations that do not reach genome-
wide significance. A third natural application, which I
have not explored, is the possibility to fine map GWAS
loci by using functional genomic information.35 Indeed,
the posterior probability that each SNP in a given genomic
region is the causal one is explicitly included in the model.
However, in current applications, around 20% of common
SNPs are neither genotyped nor successfully imputed; this
is a major limitation to fine mapping and cannot be over-
come with statistical means. As GWASs move to even
denser genotyping or sequencing, I expect that revisiting
this issue will be fruitful.Appendix A
In this appendix, I include a detailed description of the
data used in the paper.
Genetic Investigation of Anthropometric Traits
Consortium Data
I downloaded summary statistics from large GWASs of
height26 and BMI41 (Web Resources). The height summary
statistics consisted of 2,469,635 SNPs either directly geno-
typed or imputed in an average of 129,945 individuals. I
removed all SNPs with a sample size of fewer than
120,000 individuals. The BMI summary statistics consisted
of 2,471,516 summary statistics either directly genotyped
or imputed in an average of 120,569 individuals. I removed
all SNPs with a sample size of fewer than 110,000 individ-
uals. I then imputed summary statistics at SNPs identified
in the 1000 Genomes Project as described in the Material
and Methods.
Genetic Factors for Osteoporosis Consortium Data
I downloaded summary statistics from large GWASs of
bone mineral density42 (Web Resources). There were two
traits in these data: bone density measured in the femoral
neck and bone density measured in the lumbar spine. The
GWAS on femoral neck bone density consisted ofThe Am2,478,337 SNPs, and the GWAS on lumbar spine bone
density consisted of 2,468,080 SNPs. Because the sample
size at each SNP was not reported, I used the overall study
sample sizes of 32,961 (for femoral neck bone density) and
31,800 (lumbar spine bone density) as approximations of
the sample size at each SNP and imputed summary statis-
tics as described in the Material and Methods.
International Inflammatory Bowel Disease Genetics
Consortium Data
I downloaded summary statistics from a large GWAS of
Crohn disease40 (Web Resources). The downloaded data
consisted of 953,242 SNPs. Because the sample size at
each SNP was not reported, I used the overall study sample
sizes of 6,299 case and 15,148 control individuals as
approximations of the sample size at each SNP and
imputed summary statistics as described in the Material
and Methods. Note that summary statistics from a GWAS
of ulcerative colitis were also available from this site;
however, these data contained a number of false-positive
associations that were filtered by Jostins et al.40 according
to criteria that were not available to me. I thus only used
the Crohn disease association study.
Meta-analyses of Glucose and Insulin-Related Traits
Consortium Data
I downloaded summary statistics from a large GWAS of
fasting glucose levels43 (Web Resources). The downloaded
data consisted of 2,628,880 SNPs. Because the sample
size at each SNP was not reported, I used the overall study
sample size of 58,074 as an approximation of the sample
size at each SNP and imputed summary statistics as
described in the Material and Methods.
Global Lipids Genetics Consortium Data
I downloaded summary statistics from a large GWAS
of lipid traits27 (Web Resources). These data consisted of
summary statistics for association studies of four traits:
LDL cholesterol, HDL cholesterol, TGs, and TC. The HDL
data consisted of 2,692,429 SNPs genotyped or imputed
in an average of 88,754 individuals, the LDL data consisted
of 2,692,564 SNPs genotyped or imputed in an average of
84,685 individuals, the TC data consisted of 2,692,413
SNPs genotyped or imputed in an average of 89,005 indi-
viduals, and the TG data consisted of 2,692,560 SNPs geno-
types or imputed in an average of 85,691 individuals. For
all traits, I removed SNPs with a sample size of fewer
than 80,000 individuals and imputed summary statistics
as described in the Material and Methods.
To calibrate significance thresholds, I additionally used
summary statistics from the 2013 Global Lipids Genetics
Consortium paper17 (Web Resources).
Red Blood Cell Trait Data
I obtained summary statistics from a large GWAS of
red blood cell traits15 from the European Genome-phe-
nome Archive (accession number EGAS00000000132). Ierican Journal of Human Genetics 94, 559–573, April 3, 2014 569
downloaded summary statistics from association studies of
six traits: hemoglobin levels, mean cell hemoglobin
(MCH) levels, mean corpuscular hemoglobin concentra-
tion (MCHC), mean cell volume (MCV), packed cell
volume (PCV), and red blood cell count (RBC). The hemo-
globin-level data consisted of 2,593,078 SNPs genotyped or
imputed in 50,709 individuals, the MCH data consisted
of 2,586,785 SNPs genotyped or imputed in an average
of 43,127 individuals, the MCHC data consisted of
2,588,875 SNPs genotyped or imputed in an average of
46,469 individuals, the MCV data consisted of 2,591,132
SNPs genotyped or imputed in an average of 47,965 indi-
viduals, the PCV data consisted of 2,591,079 SNPs geno-
typed or imputed in an average of 44,485 individuals,
and the RBC data consisted of 2,589,454 SNPs genotyped
or imputed in an average of 44,851 individuals. I removed
all SNPs with a sample size of fewer than 50,000 individ-
uals (for hemoglobin levels) or 40,000 individuals (for
the other traits) and imputed summary statistics as
described in the Material and Methods.
Platelet Traits
Summary statistics from a large GWAS of platelet traits39
were generously provided by Nicole Soranzo. The data
consisted of summary statistics from association studies
of two traits: platelet counts and mean platelet volume.
The platelet-count data consisted of 2,705,636 SNPs geno-
typed or imputed in an average of 44,217 individuals, and
the platelet-volume data consisted of 2,690,858 SNPs
genotyped or imputed in an average of 16,745 individuals.
I removed all SNPs with sample sizes of fewer than 40,000
individuals (for platelet counts) or 15,000 individuals (for
platelet volume) and imputed summary statistics as
described in the Material and Methods.
DNase-I-Hypersensitivity Data
I downloaded DNase-I-hypersensitivity data from two
sources. The first was a set of regions defined as DNase-I
hypersensitive byMaurano et al.11 in 349 samples. I down-
loaded .bed files for 349 samples (Web Resources) on
February 13, 2013. These samples include 116 samples
from cell lines or sorted blood cells and 333 samples
from primary fetal tissues. These latter samples were
sampled from several tissues at various time points; I
treated each track as independent rather than pooling
data from tissues, given that different experiments might
have slightly different properties. The tissues in this latter
group were fetal heart, fetal brain, fetal lung, fetal kidney,
fetal intestine (large and small), fetal muscle, fetal
placenta, and fetal skin.
The second was a set of regions defined as DNase-I
hypersensitive by the Crawford lab in the context of the
ENCODE project.44 I downloaded .bed files for 53 samples
(Web Resources) on March 29, 2013. I restricted myself to
the files labeled as being generated at Duke University.
Each experiment defined a set of regions of open chro-
matin in a particular cell type or cell line.570 The American Journal of Human Genetics 94, 559–573, April 3, 2The ‘‘Duke’’ DNase-I hypersensitive sites were all of
exactly 150 bases in length, and each annotation covered
approximately 1% of the genome (range ¼ 0.4%–1.9% of
the genome). The ‘‘Maurano’’ DNase-I hypersensitive sites
were on average 514 bases long, and each covered on
average 2.7% of the genome (range ¼ 0.9%–5.1% of the
genome).Chromatin State Data
I downloaded the ‘‘genome segmentations’’ of the six
ENCODE cell lines45 (Web Resources) on December 18,
2012. I used the ‘‘combined’’ segmentation from two
algorithms. This segmentation split the genome into
nonoverlapping regions described as CTCF binding sites,
enhancers, promoter-flanking regions, repressed chro-
matin, transcribed regions, TSSs, and weak enhancers.
This segmentation was done independently in each of
six cell lines for a total of 42 annotations.
Overall, the ‘‘repressed chromatin’’ mark covered the
largest fraction of the genome on average 66% (ranging
from 60% for HUVEC cells to 70% for H1 ES cells). The
‘‘transcribed’’ mark covered on average 13%of the genome,
the ‘‘CTCF’’ mark 1% of the genome, the ‘‘enhancer’’ mark
0.9% of the genome, the ‘‘TSS’’ mark 0.7% of the genome,
the ‘‘weak enhancer’’ mark 0.4% of the genome, and
the ‘‘promoter-flanking’’ mark 0.2% of the genome. The
remainder of the genomewas notmappable by short reads,
and it was thus excluded from these annotations.Gene Models
I downloaded the Ensembl gene annotations from the
UCSC Genome Browser on May 21, 2013. Annotations of
nonsynonymous and synonymous status for all SNPs in
phase 1 of the 1000 Genomes Project were obtained
(Web Resources). Coding exons covered about 3% of the
genome, whereas 30 and 50 UTRs covered 2% and 0.6% of
the genome, respectively.Supplemental Data
Supplemental Data include 16 figures and 22 tables and can be
found with this article online at http://www.cell.com/ajhg.Acknowledgments
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Web Resources
The URLs for data presented herein are as follows:
1000GenomesProjectannotatedVCFs, ftp://ftp-trace.ncbi.nih.gov/
1000genomes/ftp/phase1/analysis_results/functional_annotation/
annotated_vcfs/
1000 Genomes Project haplotypes, ftp://ftp-trace.ncbi.nih.gov/
1000genomes/ftp/phase1/analysis_results/integrated_call_sets/
DNase-I hypersensitive sites (Duke), http://ftp.ebi.ac.uk/pub/
databases/ensembl/encode/integration_data_jan2011/byData
Type/openchrom/jan2011/fdrPeaks/
DNase-I hypersensitive sites (Maurano), http://www.uwencode.
org/proj/Science_Maurano_Humbert_et_al/
fgwas software, https://github.com/joepickrell/fgwas
Genetic Factors for Osteoporosis Consortium (GEFOS) data,
http://www.gefos.org/?q¼content/data-release
Genetic Investigation of Anthropometric Traits (GIANT)
consortium data, http://www.broadinstitute.org/collaboration/
giant/index.php/GIANT_consortium
Genome segmentation data, http://ftp.ebi.ac.uk/pub/
databases/ensembl/encode/integration_data_jan2011/byData
Type/segmentations/jan2011/hub/
Global Lipids Genetics Consortium Results (2010), http://www.
sph.umich.edu/csg/abecasis/public/lipids2010/
Global Lipids Genetics Consortium Results (2013), http://www.
sph.umich.edu/csg/abecasis/public/lipids2013/
International Inflammatory Bowel Disease Genetics Consortium
data, http://www.ibdgenetics.org/downloads.html
Meta-analyses of Glucose and Insulin-Related Traits Consortium
data, http://www.magicinvestigators.org/downloads/
UCSC Genome Browser, http://genome.ucsc.eduReferences
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